Will This Genetic Testing Name's Profit Soar 950%? Earnings Are On Deck.

Group 1 - GeneDx Holdings is highlighted as a leading stock in the IBD 50 Growth Stocks To Watch, showing a significant climb in a seven-week-long consolidation pattern ahead of its earnings report [1] - The company turned profitable in 2024, with analysts projecting substantial earnings growth for its third quarter [1] - GeneDx has recently been recognized as an IBD Breakout stock, indicating strong market performance [1] Group 2 - The stock is expected to achieve a remarkable 954% growth following its FDA Breakthrough Device Designation [2] - GeneDx has seen a 36% increase in stock price over the past two days, reflecting strong investor interest [4] - The company has cleared technical benchmarks, achieving a 90-plus Relative Strength (RS) Rating [4]